Examples of 'tofacitinib' in a sentence
Meaning of "tofacitinib"
tofacitinib (adjective) - Tofacitinib is an adjective that describes a type of medication used in the treatment of certain autoimmune diseases, such as rheumatoid arthritis. It is a pharmaceutical term and is not commonly used in general English conversation
Show more definitions
- A drug that is used to treat some immunological diseases
How to use "tofacitinib" in a sentence
Basic
Advanced
tofacitinib
Tofacitinib citrate may also have benefits.
Xeljanz contains the active substance tofacitinib.
No direct comparison between tofacitinib and adalimumab was held.
There is no specific antidote for overdose with tofacitinib.
The use of tofacitinib was not addressed in these recommendations.
Lymphomas have been observed in patients treated with tofacitinib.
The effect of tofacitinib on the development of lymphoma is uncertain.
Xeljanz is a medicine that contains the active substance tofacitinib.
Combined use of tofacitinib with tacrolimus should be avoided.
The active substance is tofacitinib.
Combined use of tofacitinib with ciclosporine should be avoided.
Xeljanz is the brand name for the drug tofacitinib.
It is not known whether tofacitinib is secreted in human milk.
Tofacitinib can be used in combination with synthetic DMARDs or as monotherapy.
The pharmacologic activity of tofacitinib is attributed to the parent molecule.
See also
Tofacitinib tablets may be crushed and taken with water.
Administration of supplemental doses of tofacitinib following dialysis is not necessary.
Tofacitinib dose should be reduced a.
Patients receiving tofacitinib.
The impact of tofacitinib on chronic viral hepatitis reactivation is unknown.
It is recommended that live vaccines not be given concurrently with tofacitinib.
Tofacitinib distributes equally between red blood cells and plasma.
The possibility exists for tofacitinib to affect host defences against malignancies.
Biological activity following administration of the present compounds is attributable to generated tofacitinib.
Treatment with tofacitinib has been associated with decreases in haemoglobin levels.
Lymphoma and other serious malignancies have been observed in patients treated with tofacitinib.
Avoid tofacitinib in patients who may have a higher risk of thrombosis.
Health care professionals should discontinue tofacitinib and promptly evaluate patients with symptoms of thrombosis.
Tofacitinib treatment should be interrupted if a patient develops a serious infection until the infection is controlled.
Two randomized studies evaluated tofacitinib and adalimumab in parallel groups versus placebo.
Tofacitinib was discontinued and the patient recovered after treatment with standard doses of antiviral medication.
The researchers then tested whether giving tofacitinib seven weeks after grafting could reverse alopecia.
Impact of other medicinal products on PK of tofacitinib.
The effect of tofacitinib on the development and course of malignancies is not known.
NMSCs have been reported in patients treated with tofacitinib.
Treatment with tofacitinib was associated with an increased incidence of lymphopenia compared to placebo.
Your son has paid for an upgrade to the Tofacitinib.
The benefit of tofacitinib should be evaluated in the context of the adverse effects described.
The first JAK inhibitor to reach clinical trials was tofacitinib.
Day agreed that tofacitinib could offer people with vitiligo new hope.
Many clinical trials are ongoing involving JAK inhibitors such as ruxolitinib and tofacitinib.
Potential for tofacitinib to influence the PK of other medicinal products.
Examples of JAK inhibitors preferably include compounds selected from among Tofacitinib and Ruxolitinib.
Tofacitinib does not currently have Marketing Authorisation in the EU for any indication.
Uses of Tofacitinib.
Tofacitinib with and without MTX in comparison to ADA with MTX.
If therapy is interrupted, restarting treatment with tofacitinib can be considered.
Tofacitinib is an expensive drug, generally similar to biological DMARDs.
If biologic treatment has failed, tofacitinib may be considered, where approved.
Furthermore, immunizations with live vaccines should be avoided by tofacitinib users.
